Called out for tripling price of potential drug for Covid patients, company says increase planned for months

A letter from two influential members of Congress raised concerns about the tripling in price of a possible diarrhea treatment for Covid-19 or HIV/AIDS patients. But the San Francisco company that makes the drug said it did nothing wrong and its price increase four weeks ago had been planned months ahead. The letter Monday from House Oversight Committee Chairwoman Carolyn Maloney and Peninsula Rep. Jackie Speier ? both Democrats ? asked Jaguar Health Inc. (NASDAQ: JAGX) to turn over paperwork?

Click to view original post